Wells Fargo raised the firm’s price target on C4 Therapeutics to $8 from $7 and keeps an Equal Weight rating on the shares following quarterly results. The firm notes the update gets it a bit more confident in cemi plus dex’s safety profile as it continues to dose escalate in the Phase 1/2 MM arm. Timelines were reiterated for updated data in the second half of 2024, Wells adds.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
- C4 Therapeutics presents new data for CFT1946 at AACR
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024